Citations

Institution: Mayo Clinic Clear

Showing 10 of 108083 citations.

A Phase I Clinical Study and In Vivo Findings with PT-112, a Novel Immunogenic Cell Death–Inducing Small Molecule, in Relapsed or Refractory Multiple Myeloma
Kourelis, Taxiarchis , Ailawadhi, Sikander , Vogl, Dan T. , Gibson, Sarah E. , Sharik, Meaghen E. , Du, Megan T. , Ames, Tyler D. , Yim, Christina Y. , Baeck, Johan , Price, Matthew R. , Jimeno, J. , Chesi, Marta , Jimeno, Jose M , Bergsagel, P. Leif , Ailawadhi, Sikander , Gibson, Sarah E , Bergsagel, P. Leif

Clinical Cancer Research | August 12, 2025 | Volume: 31 | Issue: 21 | Pages: 4518-4528

10.1158/1078-0432.ccr-24-2574 | PMID 40795066 Get It

Abstract Purpose: R,R-1,2 cyclohexanediamine-pyrophosphato-platinum(II) (PT-112) is a novel immunogenic cell death–inducing small molecule under phase II development in several cancer types. It inhibits ribosome biogenesis and causes organelle stresses, leading to selective immunogenic cell death in cancer cells. The possibility of PT-112’s pyrophosphate moiety driving high drug concentrations to bone sites of disease has led to an interest in PT-112’s use in multiple myeloma. In this study, we present findings from phase I and in vivo studies for PT-112 in relapsed or refractory multiple myeloma. Experimental Design: PT-112 biodistribution was analyzed in mice via laser ablation inductively coupled plasma mass spectrometry. The activity of PT-112 was assessed in de novo and transplantable Tg(Igkv3-5*-MYC)#Plbe (Vk*MYC) multiple myeloma mouse models as monotherapy or combination therapies. M-spike levels and survival were measured. A phase I dose escalation study of PT-112 monotherapy was conducted using a 3 + 3 design in patients with heavily pretreated relapsed or refractory multiple myeloma with exhausted available therapies. Results: In vivo biodistribution imaging revealed high concentrations in the bone, kidney, lung, skin, and liver. PT-112 was active in Vk*MYC multiple myeloma mouse models, both alone and in combination. Phase I data showed that PT-112 monotherapy was safe and well-tolerated, establishing a recommended phase II dose of 360 mg/m2 on days 1, 8, and 15 of a 28-day cycle. Confirmed responses and other signals of activity were observed. Conclusions: These results suggest a lack of cross-resistance with the standard of care and support the translational value of the Vk*MYC model system. Further clinical investigation of PT-112 is warranted in multiple myeloma.
Metrics for Phonoenterogram Analytics Towards AI Powered Diagnosis of Bowel Diseases: Feasibility Meal Study in a Healthy Subject
Gopalakrishnan, Keerthy, Asadimanesh, Naghmeh, Sood, Divyanshi, Rapolu, Swetha, Lee, Jieun , Patel, Bhumi, Arunachalam, S P , Mohan, Anmol , Patel, Bhumi, Dilmaghani, Saam , Arunachalam, Shivaram P.

2025 IEEE International Conference on Electro Information Technology (eIT) | August 12, 2025 | Volume: No volume available | Issue: No issue available | Pages: 1-6

10.1109/eit64391.2025.11103636 Get It

Understanding the sexual concerns of older women presenting for care to women’s health clinics: a cross-sectional study
Karam, J H, Shufelt, Chrisandra , Kingsberg, Sheryl A. , Cole, Kristin , Kapoor, Ekta , Mara, Kristin C. , Winham, Stacey, Mara, Kristin C , Shufelt, Chrisandra L , Karam, Jana, Winham, Stacey J. , Kling, Juliana M. , Faubion, Stephanie S.

Menopause | August 12, 2025 | Volume: 32 | Issue: 12 | Pages: 1095-1102

10.1097/gme.0000000000002617 | PMID 40794483 Get It

Objective: To compare the prevalence of female sexual dysfunction (FSD) and distress between sexually active midlife women (50-64 y) and older women (65+ y) presenting for care at women’s health clinics at a tertiary care center. Methods: This cross-sectional study included women aged 50 and above who received care at Mayo Clinic women’s health clinics in Rochester, MN; Scottsdale, AZ; and Jacksonville, FL, between May 1, 2015, and August 31, 2022. Sexual function and distress were compared between midlife and older women using the Female Sexual Function Index (FSFI), Female Sexual Distress Scale-Revised (FSDS-R), and self-reported sexual health concerns. Results: Among 3,465 sexually active women, older women were less likely to report loss of sexual desire (33.4% vs. 47.6%; P <0.001) and reduced genital sensation (13.0% vs. 16.9%; P =0.024) compared with midlife women. There were no significant differences for vaginal dryness, painful intercourse, or arousal/orgasm difficulties. FSFI scores were higher in older women for desire (3.0 vs. 2.4; P <0.001) and lubrication (3.9 vs. 3.6; P <0.001). While total FSFI scores were similar between older and midlife women (21.2 vs. 22.2; P =0.11), sexually related distress was lower in older women compared with midlife women (13.0 vs. 15.0; P =0.015). The prevalence of FSD (defined as FSFI score ≤26.55 and FSDS-R score ≥11) was similar between groups (51.8% vs. 56.2%; P =0.056). Conclusions: Older women experienced FSD at similar rates as midlife women but reported less sexual distress, potentially reflecting lower expectations regarding sexual function. Addressing sexual health concerns in older women may enhance quality of life.
Poly-4-Hydroxybutyrate as a Novel Biomaterial in Personalized Breast Surgery: A Systematic Review and Meta-Analysis
Escandón, Joseph M. , Nugent, Ajani, Boyd, Carter J. , Boyd, Carter J , Escandón, Joseph M , Karp, Nolan S. , Vyas, Krishna S. , Kreutz‐Rodrigues, Lucas

Journal of Personalized Medicine | August 12, 2025 | Volume: 15 | Issue: 8 | Pages: 368

10.3390/jpm15080368 | PMID 40863430 Get It

Background/Objectives: In the search for optimal meshes and matrices in breast surgery, poly-4-hydroxybutyrate (P4HB) has emerged as a promising alternative. This review evaluates the clinical application of P4HB scaffolds, focusing on complication rates and surgical outcomes. Methods: A systematic search was conducted using PubMed and ScienceDirect. Clinical studies assessing perioperative outcomes and complications associated with P4HB scaffolds in breast surgery were included. Results were stratified into aesthetic and reconstructive surgery categories. Meta-analysis was implemented to assess the rate of complications and satisfaction. Results: This systematic review included 13 studies evaluating the use of P4HB scaffold in breast reconstruction (636 cases) and aesthetic breast surgery (462 patients). Breast reconstruction studies were all retrospective, mainly reporting two-stage, prepectoral, immediate reconstructions. Aesthetic studies included both prospective and retrospective designs, with varied implant planes and incision patterns. P4HB use was associated with high satisfaction (95.5%) and favorable outcomes, including lower odds of wound complications (log-OR = −1.135, p = 0.003). Complication rates were low across both surgical categories. P4HB scaffold showed promise in supporting implant-based procedures and maintaining breast shape over time, with minimal increase in surgical time and stable anthropometric measurements. Conclusions: The use of P4HB scaffold in breast reconstruction and aesthetic surgery shows promising results, notably in reducing wound-related complications. Breast reconstruction studies report low complication rates and favorable patient-reported outcomes. In aesthetic procedures, P4HB contributes to improved long-term breast shape and high satisfaction. Despite encouraging findings, further research is necessary to validate long-term efficacy and refine surgical approaches.
Genetic and Clinical Characterization of a Large Cohort with Suspected Monogenic Stone Disease
Cogal, Andrea G. , Ali, Ahmed E. , Arnous, Muhammad G. , Zhou, Le‐Ting , Arroyo, Jennifer, Seide, Barbara M., Reynolds, Laura M. , Kennedy, Gabrielle N. , Milliner, Dawn S. , Sas, David J. , Harris, Peter C. , Cheungpasitporn, Wisit , Tan-Arroyo, Jennifer , Alhadi, Abdulmueti , Arroyo, Jennifer , Seide, Barbara M , Rossler, Kalina J , Reynolds, Laura M , Kennedy, Gabrielle N , Elbarougy, Doaa E , Goldfarb, David S , Milliner, Dawn , Lieske, John C , Harris, Peter C , Cheungpasitporn, Wisit , Alhadi, Abdulmueti , Elbarougy, Doaa E. , Goldfarb, David S. , Lieske, John C.

Clinical Journal of the American Society of Nephrology | August 12, 2025 | Volume: 20 | Issue: 12 | Pages: 1670-1682

10.2215/cjn.0000000817 | PMID 40794449 Get It

Key Points Genetic testing of individuals suspected of monogenic urinary stone disease resolved 34% of families with 22 different genes detected. Resolved individuals had a lower baseline and last visit eGFR and earlier age of stone presentation than the unresolved group. Specific phenotypes and younger diagnostic age were associated with a monogenic cause, allowing refinement of future screenings. Background Urinary stone disease with a clear genetic cause, monogenic stone disease (MSD), is increasingly recognized as a significant proportion of the total population. When MSD is suspected, genetic testing provides a firm diagnosis that can alter management and treatment. Here, we present testing results from a large cohort with suspected MSD. Methods Patients with features suggestive of MSD (early onset, family history, frequent stones, nephrocalcinosis [NC], and/or CKD) were recruited by the Rare Kidney Stone Consortium and genotyped for up to 160 known or candidate MSD genes via a targeted massively parallel sequencing panel. We compared clinical and biochemical features between genetically resolved MSD and unresolved individuals. Results Of 426 families (657 patients) enrolled, 145 (34%) were resolved with identified disease associated variants in 22 known MSD genes. Ninety-nine families were biallelic, 37 monoallelic, and two digenic. An additional 21 of the 231 screened family members were resolved. Genes identified in ten or more families include the following: AGXT , HOGA1 , SLC34A3 , CYP24A1 , SLC3A1 , and CLCN5 . Compared with the unresolved group, MSD probands had a lower baseline and last visit eGFR, earlier age of stone presentation, and more stone events and procedures/year of life. The resolve rate was higher in those <16 years, and NC was seen earlier in the MSD group. Overall, NC was a risk factor for lower eGFR. Among the specific disorders, patients with primary hyperoxaluria had the earliest age of stone and NC diagnosis, and as expected, the highest urinary oxalate level. Conclusions Our study emphasizes the value of selecting patients enriched for factors associated with MSD, and comprehensive genetic testing to achieve a high yield of genetic diagnoses. Significant clinical and biochemical characteristics of patients with MSD were defined. A definitive MSD diagnosis facilitates individualized management and strategies to delay disease progression in probands and affected family members.
Liver transplantation indications and strategies in polycystic liver disease: A european survey
Duijzer, Renée , Ferri, Flaminia , Nevens, Frederik , Verbeek, Jef , Colmenero, Jordi , Taubert, Richard , Fraňková, Soňa , Taner, Timucin, Alwayn, Ian P J , Ferri, Flaminia , Nevens, Frederik , Papatheodoridis, George , Verbeek, Jef , Colmenero, Jordi , Goossens, Nicolas , Milkiewicz, Piotr , Taubert, Richard , Frankova, Sona , Taner, Timucin , Gevers, Tom J.G. , Drenth, Joost P H , Goossens, Nicolas , Milkiewicz, Piotr , Wilde, Roeland F. de , Drenth, Joost P.H.

Liver Transplantation | August 12, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/lvt.0000000000000700 | PMID 40793999 Get It

Background & Aims: Liver transplantation (LT) remains the only cure for severe polycystic liver disease (PLD). However, LT indications and strategies vary across Europe, resulting in (unwanted) practice variation and unequal access to care for patients with PLD. This study aimed to (1) identify existing PLD-specific LT criteria across European countries, (2) assess which criteria are considered relevant by specialist, and (3) map the variation in liver-kidney transplant strategies among patients with autosomal dominant polycystic kidney disease (ADPKD). Methods: National PLD-specific LT criteria were collected, and if unavailable ERN RARE-Liver representatives from that country were asked to provide information. An online survey was conducted amongst hepatologists, LT surgeons, and nephrologists managing patients with PLD. The survey assessed relevant LT indications/listing requirements, clinical case evaluations, and explored preferences for liver-kidney transplantation in patients with ADPKD. Results: Defined LT criteria for patients with PLD were available in only 8 of the 17 assessed countries and showed substantial variation. Sixty-nine clinicians (43 hepatologists, 15 surgeons, 11 nephrologists), predominantly from LT centers (75.4%), completed the survey. Key LT indications were recurrent liver cyst infections (78.3%), significant impaired quality of life (75.4%), and severe malnutrition (75.4%). In ADPKD simultaneous liver-kidney transplantation (SLK) was preferred by 40.4% of respondents, primarily due the favorable immunological profile (47.6%) and prevention of renal failure (33.3%). In contrast, those favoring a liver-first approach (30.8%), followed by sequential kidney transplant, highlighted the potential harm to the kidney graft during SLK (62.5%). Conclusions: Uniform PLD-specific LT criteria in Europe are lacking. While recurrent liver cyst infections, decreased quality of life, and malnutrition are widely recognized as crucial LT indications, they are insufficiently reflected in existing criteria, contributing to unequal access to LT. Moreover, considerable variation exists in liver-kidney transplantation for ADPKD patients, with a current lack of evidence to support one approach over another.
Revealing disparities: American Indians are deferred and denied for liver transplant at a higher rate due to psychological reasons
Elmasry, Sandra , Lizaola‐Mayo, Blanca , Delafield, Nathan L. , Milam, Adam J. , Dickson, Rolland C. , Chascsa, David M. , Chascsa, David M , Lizaola-Mayo, Blanca , Milam, Adam J

Liver Transplantation | August 12, 2025 | Volume: 32 | Issue: 2 | Pages: 278-282

10.1097/lvt.0000000000000704 | PMID 40793991 Get It

When Less Is More: Rethinking Neck Ultrasound Surveillance in Older Adults with Thyroid Cancer
Lyerly, Mac, Chindris, Ana-Maria , Desai, Kaniksha

Clinical Thyroidology® | August 12, 2025 | Volume: 37 | Issue: 8 | Pages: 273-276

10.1089/ct.2025;37.273-276 Get It

Alcohol use disorder, but not current alcohol use is associated with falls among people with HIV in care
Dai, Mindy , Chander, Geetanjali , Webel, Allison R. , Whitney, Bridget M. , Christopoulos, Katerina , Moore, Richard D. , Keruly, Jeanne , Bamford, Laura , Cachay, Edward R. , McCaul, Mary E. , Fredericksen, Rob J. , Yendewa, George A. , Saag, Michael S. , Crane, Heidi M. , Cachay, Edward, Delaney, Joseph A. , Mayer, Kenneth Hugh , Christopoulos, Katerina A. , Napravnik, Sonia , Lesko, Catherine R. , Drumright, Lydia N.

AIDS | August 12, 2025 | Volume: 39 | Issue: 14 | Pages: 2094-2102

10.1097/qad.0000000000004317 | PMID 40792693 Get It

Background: Current understanding of associations between alcohol use and falls among people with HIV (PWH) is limited due to few and inconsistent studies. Given the prevalence of heavy episodic alcohol use reported among PWH, this remains an important question. Methods: Alcohol use was measured using the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) and self-reported alcohol use treatment and/or diagnosis of alcohol use disorder (collectively AUD) among PWH at eight CFAR Network of Integrated Clinical Systems (CNICS) sites from 2021 to 2024. Falls were self-reported using the components of the Falls Risk for Older People in the Community (FROP-Com) questionnaire. Cross-sectional associations between alcohol use and falls were examined using relative risk models adjusted for age, sex, race/ethnicity, and geographic location. Results: Among 5729 PWH, mean age was 55 years; 42% reported White and 41% reported Black/African American race/ethnicity; and 81% were male. Mean AUDIT-C score was 1.9 (range: 0–12); 27% reported heavy episodic drinking; 22% had AUD; and 22% reported falling in the past year. Reporting at least one fall in the past year was not associated with any measure of current alcohol use. AUD was associated with reporting at least one fall [prevalence ratio = 1.54; 95% confidence interval (CI) 1.39–1.70] and number of falls [one fall: prevalence ratio = 1.27 (95% CI: 1.08–1.50); at least two falls: prevalence ratio = 1.84 (95% CI: 1.58–2.15)]. Conclusion: Among PWH, 22% reported falling, which was associated with AUD, but not current alcohol use, suggesting that a mechanism other than acute intoxication could be responsible. Further longitudinal research is warranted to explore mechanisms for why AUD, but not current alcohol use, is associated with falls.
Individualized Learning in Robotic Ileal pouch-anal anastomosis
Violante, Tommaso , Sassun, Richard , Mishra, Nitin , Merchea, Amit , Violante, Tommaso , Sassun, Richard , Ferrari, Davide, Behm, Kevin T. , Vierkant, Robert A. , Larson, David W.

Annals of Surgery | August 12, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/sla.0000000000006907 | PMID 40792635 Get It

Objective: This study establishes objective benchmarks for robotic ileal pouch-anal anastomosis (IPAA) proficiency, evaluating individual surgeon learning curves using risk-adjusted cumulative sum (RA-CUSUM) analysis. Summary Background Data: IPAA is a standard surgical treatment for conditions like refractory ulcerative colitis; robotic assistance offers potential advantages. However, the robotic IPAA learning curve is not clearly defined. Conventional analyses often overlook significant inter-surgeon variability and patient-specific factors, hindering surgical training optimization. Methods: A multi-site retrospective analysis of 123 consecutive robotic IPAA procedures performed by 11 surgeons between June 2015 and December 2023 was conducted. Patient-related variables were used for risk adjustment, and RA-CUSUM charts were generated to assess 30-day complications, operative time, and length of hospital stay at both aggregate and individual surgeon levels. Results: Aggregate RA-CUSUM data indicated general improvement trends for operative time and length of stay, alongside higher-than-expected complication rates in the early phase. Disaggregated analyses at the individual surgeon level revealed significant heterogeneity in performance trajectories and learning patterns across all three outcomes, directly challenging the concept of a standardized, uniform learning curve. Although postoperative complication and length of stay outcomes did not significantly differ between surgeons, operative time varied significantly. Conclusions: The acquisition of skill in robotic IPAA is a highly individualized process, suggesting the traditional uniform learning curve model is insufficient for contemporary surgical education. These findings strongly advocate for a shift towards personalized training paradigms that incorporate deliberate practice, targeted feedback, and simulation to optimize learning and patient outcomes.